Art

J-GLOBAL ID：201802222892801225   Reference number：18A1853574

Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120

疾患修飾性抗リウマチ薬での以前の治療にもかかわらず活動性関節リウマチを有する日本人患者におけるゴリムマブ単剤療法の臨床効果,X線検査,および安全性結果:120週を通じたGO-MONO試験の最終結果

Author (12)： TAKEUCHI Tsutomu (Keio Univ. School of Medicine, Tokyo, JPN) ,  HARIGAI Masayoshi (Tokyo Women’s Medical Univ., Tokyo, JPN) ,  TANAKA Yoshiya (Univ. Occupational and Environmental Health, Fukuoka, JPN) ,  YAMANAKA Hisashi (Tokyo Women’s Medical Univ., Tokyo, JPN) ,  ISHIGURO Naoki (Nagoya Univ., Aichi, JPN) ,  YAMAMOTO Kazuhiko (Univ. Tokyo, Tokyo, JPN) ,  MIYASAKA Nobuyuki (Tokyo Medical and Dental Univ., Tokyo, JPN) ,  KOIKE Takao (Sapporo Medical Center NTT EC, Sapporo, JPN) ,  UKYO Yoshifumi (Janssen Pharmaceutical K.K., Tokyo, JPN) ,  ISHII Yutaka (Janssen Pharmaceutical K.K., Tokyo, JPN) ,  YOSHINARI Toru (Mitsubishi Tanabe Pharma Corp., Tokyo, JPN) ,  BAKER Daniel (Janssen Res. & Dev., LLC, PA, USA)
Material： Modern Rheumatology  (Mod Rheumatol)
Volume： 28  Issue： 5  Page： 770-779  Publication year： Sep. 2018 
JST Material Number： L5142A  ISSN： 1439-7595  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *antirheumatic drug ,...
Semi thesaurus term： disease modifying antirheumatic drug ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1853574&from=J-GLOBAL&jstjournalNo=L5142A") }}

JST classification (2)： Treatment for immunologic diseases,allergic diseases.  (GD04030Y) ,  Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D)

Substance index (1)： Methotrexate

Reference (26)：

• Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2014;24:33-40.
• Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LALM, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44:2009-17.
• Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
• Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol. 2004;31:1532-7.
• Lillegraven S, van der Heijde D, Uhlig T, Kvien TK, Haavardsholm EA. What is the clinical relevance of erosions and joint space narrowing in RA? Nat Rev Rheumatol. 2012;8:117-20.

Terms in the title (12)： 疾患修飾性抗リウマチ薬 ,  治療 ,  関節リウマチ ,  日本人 ,  患者 ,  ゴリムマブ ,  単剤 ,  療法 ,  臨床効果 ,  X線検査 ,  安全性 ,  試験